D.E. Shaw & Co’s Bio-Rad Laboratories Class A BIO Stock Holding History

D.E. Shaw & Co’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-10,000	Closed	-$4.2M	–	4449
2022 Q4	$4.2M	Sell	10,000 -500	-5%	-$202K	﹤0.01%	2255
2022 Q3	$4.38M	Buy	10,500 +10,000	+2,000%	+$4.99M	0.01%	2251
2022 Q2	$248K	Sell	500 -10,600	-95%	-$5.52M	﹤0.01%	4449
2022 Q1	$6.25M	Sell	11,100 -13,000	-54%	-$7.84M	0.01%	2066
2021 Q4	$18.2M	Buy	24,100 +1,100	+5%	+$823K	0.02%	1149
2021 Q3	$17.2M	Buy	+23,000	New	+$17.2M	0.02%	1123
2020 Q4	–	Sell	-1,500	Closed	-$773K	–	3918
2020 Q3	$773K	Hold	1,500	–	–	﹤0.01%	3011
2020 Q2	$677K	Buy	+1,500	New	+$662K	﹤0.01%	3162
2019 Q3	–	Sell	-7,600	Closed	-$2.38M	–	3810
2019 Q2	$2.38M	Hold	7,600	–	–	﹤0.01%	2127
2019 Q1	$2.32M	Buy	+7,600	New	+$2.05M	﹤0.01%	2051

Other funds holding BIO

First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

D.E. Shaw & Co's BIO Position: Q1 2026 in Review

D.E. Shaw & Co increased its Bio-Rad Laboratories Class A (BIO) stake by 69% in Q1 2026, buying an estimated $955K and bringing the position to 8,145 shares worth $2.27M. The position accounts for ﹤0.01% of the portfolio, ranked #2825.

D.E. Shaw & Co first reported a position in BIO in Q2 2013 and has held it in 52 quarters since. The position peaked at $59.6M in Q3 2018. 391 funds tracked by Wall St. Rank hold BIO as of Q1 2026.

D.E. Shaw & Co held 8,145 shares of Bio-Rad Laboratories Class A worth $2.27M as of Q1 2026.
D.E. Shaw & Co bought 3,315 Bio-Rad Laboratories Class A shares in Q1 2026, an estimated $955K.
Bio-Rad Laboratories Class A made up ﹤0.01% of D.E. Shaw & Co's portfolio in Q1 2026, its #2825 holding.
D.E. Shaw & Co first reported a position in Bio-Rad Laboratories Class A in Q2 2013 and has held it in 52 quarters since.
D.E. Shaw & Co's Bio-Rad Laboratories Class A position peaked at $59.6M in Q3 2018.
391 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q1 2026.

Based on D.E. Shaw & Co's 13F filing for Q1 2026, filed 15 May 2026.